Rigel Pharmaceuticals reported $16.61M in Gross Profit on Sales for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Agenus AGEN:US $ 25.4M 6.02M
Amgen AMGN:US $ 4677M 451M
Anika Therapeutics ANIK:US $ 21.8M 3.67M
Astrazeneca AZN:US 9.11B 169M
AstraZeneca AZN:LN 8.94B 2.9B
Biomarin Pharmaceutical BMRN:US $ 402.39M 72.33M
Bristol Myers Squibb BMY:US $ 9177M 452M
ChemoCentryx CCXI:US 5.25M 3.24M
Daiichi Sankyo 4568:JP Y 189062M 10573M
Eli Lilly And LLY:US $ 5737.9M 211.8M
Halozyme Therapeutics HALO:US $ 101.36M 20.94M
Intrexon XON:US $ 6.11M 12.44M
IONIS PHARMACEUT IONS:US $ 438M 307.99M
Karyopharm Therapeutics KPTI:US $ 46.24M 79.28M
Ligand Pharmaceuticals LGND:US $ 40.99M 19.5M
MacroGenics MGNX:US 11.05M 2.15M
Neurocrine Biosciences NBIX:US $ 306M 1.9M
Pfizer PFE:US $ 15651M 1516M
Regeneron Pharmaceuticals REGN:US $ 2560.2M 1408.9M
Ultragenyx Pharmaceutical RARE:US $ 73.83M 6.04M